Trials / Completed
CompletedNCT00661167
Phase II Study of ABI-007 for Gastric Cancer
Phase II Study of ABI-007 by Tri-weekly Schedule for Patients With Unresectable or Recurrent Gastric Cancer Refractory to 5-FU Containing Regimen.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Taiho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of tri-weekly ABI-007 for recurrence or unresectable gastric cancer patients who have received one prior regimen containing fluoropyrimidine and developed disease progression or recurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-007 | ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-05-01
- Completion
- 2011-12-01
- First posted
- 2008-04-18
- Last updated
- 2012-01-18
Locations
10 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00661167. Inclusion in this directory is not an endorsement.